A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL)
Latest Information Update: 31 Jan 2022
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Vincristine (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 13 Jan 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 25 Jun 2021 Planned End Date changed from 1 Feb 2023 to 21 Jan 2024.
- 25 Jun 2021 Planned primary completion date changed from 1 Feb 2022 to 21 Jan 2023.